Macrophage activation syndrome (MAS) is a serious, life-threatening, complication,
characterized by generalized, multisystem, inflammatory response, which can affect
almost every organ system, resulting in multiple organ dysfunction [
[1]
]. Rheumatic diseases, infections, hematologic malignancies, and certain drug classes
have been identified as potential triggers of MAS [
[1]
,
[2]
]. Interleukin (IL)−1β over-secretion provokes to cytokine storm, involving IL-6,
IL-18 and interferon-γ, which contribute to multiple organ dysfunction [
[2]
]. Therefore, despite the fact that corticosteroids and cyclosporine remain the cornerstone
for the treatment of MAS, anti-cytokine biologic therapies have also emerged as potential
treatment options for this entity [
[3]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Macrophage activation syndrome.Hematol Oncol Clin N Am. 2015; 29: 927-941https://doi.org/10.1016/j.hoc.2015.06.010
- Macrophage Activation-like syndrome: a distinct entity leading to early death in sepsis.Front Immunol. 2019; 10 (Published 2019 Jan 31): 55https://doi.org/10.3389/fimmu.2019.00055
- Understanding of cytokines and targeted therapy in macrophage activation syndrome.Semin Arthritis Rheum. 2021; 51: 198-210https://doi.org/10.1016/j.semarthrit.2020.12.007
- Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.Clin Rheumatol. 2018; 37: 3329-3335https://doi.org/10.1007/s10067-018-4095-1
- Current treatment options and safety considerations when treating adult-onset Still's disease.Expert Opin Drug Saf. 2020; 19: 1549-1558https://doi.org/10.1080/14740338.2020.1839411
- Drug retention rates of biological agents in adult onset Still's disease.Semin Arthritis Rheum. 2021; 51: 1-6https://doi.org/10.1016/j.semarthrit.2020.09.014
- Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial.Cell Rep Med. 2022; 3100817https://doi.org/10.1016/j.xcrm.2022.100817
- Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial.Crit Care Med. 2016; 44: 275-281https://doi.org/10.1097/CCM.0000000000001402
- ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients.J Innate Immun. 2022; 14: 218-228https://doi.org/10.1159/000519090
- Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.Clin Exp Rheumatol. 2022; 40: 1598-1599https://doi.org/10.55563/clinexprheumatol/iqdzl9
Article info
Publication history
Published online: January 05, 2023
Accepted:
January 3,
2023
Received in revised form:
December 28,
2022
Received:
December 13,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
